Arcus Biosciences, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, Read MoreArcus Biosciences, Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Arcus Biosciences, Inc.
Score
Recent News
Earnings Per Share
Score 2.00/5
Arcus Biosciences, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.20/5
Arcus Biosciences, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
Net Margin
Score 0.60/5
Arcus Biosciences, Inc.
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
Leverage
Score 3.00/5
Arcus Biosciences, Inc.
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios
